Indazolyl-containing hydroxamic acid derivative and use thereof
By developing an indazolyl-containing hydroxamic acid derivative, multi-target inhibition of histone deacetylase and tyrosine kinase is achieved, and the poor effect of existing drugs in multi-target therapy is solved. Problem, significantly improving the therapeutic effect of various malignant tumors.
Patent Information
- Application Number
- PCT/CN2024/090847
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2024-04-30
- Publication Date
- 2024-11-21
AI Technical Summary
Existing anti-tumor drugs are difficult to effectively inhibit multiple targets at the same time, such as histone deacetylases and tyrosine kinases, resulting in poor therapeutic effects and many side effects, especially in multiple tumor types.
Develop an indazolyl-containing hydroxamic acid derivative that can simultaneously inhibit histone deacetylase 1, histone deacetylase 6 and two tyrosine kinases (VEGFR2 and PDGFR-β) as a multi-target Point inhibitors, used to treat diseases mediated by these enzymes.
This compound can significantly inhibit the activity of multiple targets, improve the effect of treating multiple malignant tumors, reduce the metabolic problems caused by drug combination, enhance biological activity, and show excellent inhibition in in vitro drug efficacy detection ability.
Smart Images

Figure CN2024090847_21112024_PF_FP_ABST
Abstract
Description
A hydroxamic acid derivative containing indazole and its application Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to an indazole-containing hydroxamic acid derivative and application thereof. Background Art
[0002] Tyrosine kinases are a class of proteins with tyrosine kinase activity. They catalyze the transfer of a phosphate group from ATP to tyrosine residues on many important proteins, causing phosphorylation and activating downstream signaling pathways. Protein tyrosine kinases play a crucial role in intracellular signaling pathways, regulating a range of physiological and biochemical processes, including cell growth, differentiation, and cell death. Dysregulation of protein tyrosine kinase function can lead to a range of diseases, including cancer. The development, metastasis, and angiogenesis of many tumors are closely linked to abnormal expression of tyrosine kinases. In particular, certain tyrosine kinase receptors are abnormally expressed in solid tumor cells. Among them, the vascular endothelial cell growth factor receptor (VEGFR) is highly expressed in many tumor cells and tumor vascular endothelial cells, and the platelet-derived growth factor receptor (PDGFR) is abnormally expressed in fibroblasts within the tumor stroma. The autocrine loop formed by its ligands and receptors is directly involved in the development and progression of tumor cells. For example, the vascular endothelial growth factor receptor (VEGFR) is present in melanoma; the platelet-derived growth factor receptor (PDGFR) is present in glioma; and the stem cell growth factor receptor (KIT) is present in small cell lung cancer. Similar loops are also found in meningiomas, neuroendocrine tumors, ovarian cancer, prostate cancer, and pancreatic cancer. This loop is closely related to the development and progression of tumors.
[0003] Furthermore, the development, progression, and metastasis of solid tumors all rely on tumor angiogenesis, which provides essential nutrients and oxygen for tumor growth. Tumor angiogenesis is a crucial process for the infiltration, migration, and proliferation of tumor cells. The vascular endothelial growth factor receptor family (VEGFR) and the platelet-derived growth factor receptor family (PDGFR) are directly linked to tumor development and angiogenesis. As the most potent known vascular permeabilizer and a specific mitogen for endothelial cells, VEGF plays a crucial role in endothelial cell proliferation, migration, and vascularization. Its expression level shows a clear positive correlation with the degree of vascularization in tumor tissue. VEGF primarily exerts its biological effects by phosphorylating the high-affinity receptors VEGFR-1 and KDR on endothelial cells, which have distinct signal transduction pathways. KDR plays a key role in tumor growth, metastasis, and angiogenesis. Platelet-derived growth factor (PDGF) and its receptor (PDGFR) are involved in the pathogenesis of various tumors and play a crucial role in angiogenesis. PDGF exerts its cellular biological effects through its receptor (PDGFR). PDGFR maintains vascular wall integrity by regulating the proliferation and migration of pericytes and vascular smooth muscle cells, promoting the formation of new blood vessels in tumors. Furthermore, it promotes tumor growth by altering the tumor microenvironment.
[0004] Because abnormal expression of tyrosine kinases is closely linked to tumor development, metastasis, and angiogenesis, the development of drugs targeting tyrosine kinases has become a hot topic in international anti-tumor drug research. In particular, targeting angiogenesis to inhibit tumor angiogenesis, block tumor nutrient supply and migration pathways, and prevent tumor growth and metastasis has become a new strategy for tumor treatment. Aberrant expression of KDR or PDGFR receptors plays a key role in tumor angiogenesis, making them ideal targets for anti-tumor drug therapy. Furthermore, sorafenib and sunitinib (SU11248), two US FDA-approved anti-tumor drugs that primarily inhibit KDR and PDGFR receptor tyrosine kinases, have been clinically proven to be highly effective and have minimal side effects.
[0005] Histone deacetylases (HDACs) are a class of intracellular metalloproteinases that play a crucial role in chromatin structural modification and gene expression regulation. In cancer cells, overexpression of HDACs leads to increased histone-DNA binding, resulting in abnormal chromatin conformational changes. Simultaneously, the expression of cell cycle inhibitors is suppressed, the stability and DNA binding ability of the tumor suppressor p53 decrease, and the expression of hypoxia inducible factor-1 (HIF-1) and vascular endothelial growth factor (VEGF) increases. In mammalian cells, the balance between acetylation and deacetylation plays a critical role in gene transcription and the function of various cellular proteins. Histone acetylation status is regulated by histone acetyltransferases (HATs) and histone deacetylases (HDACs). The dynamic balance between HATs and HDACs controls chromatin structure and gene expression, and their dysfunction is a key molecular mechanism of tumor development and progression. HDACs belong to the deacetylase superfamily. HDACs play an important role in chromatin remodeling, gene repression, cell cycle regulation and differentiation. Abnormal function of histone deacetylase in tumor cells can lead to the transcriptional inhibition of many genes and inhibit the expression of tumor suppressor genes. Data have reported that HDAC1 mRNA and protein levels are highly expressed in gastric cancer, prostate cancer, colon cancer and liver cancer tissues, and are associated with the TNM stage and lymph node metastasis of the tumor. Studies have found that inhibiting the activity of HDACs can effectively inhibit cancer cell proliferation, induce cell cycle arrest and promote cell apoptosis. Therefore, HDACs have become a new target for the design of anticancer drugs, and the development of HDAC inhibitors (HDACi) is considered an effective strategy for tumor treatment. Hydroxamic acid small molecule HDACi is a class of HDACi that has received much attention in recent years and has shown good anti-tumor activity both in vivo and in vitro. HDAC has developed relatively maturely as an anti-cancer target drug. In 2006, the American pharmaceutical company Merck launched Vorinostat for the treatment of cutaneous T-cell lymphoma. This was the first HDAC inhibitor to be marketed. Since then, several HDAC inhibitors have been approved for marketing, including romidepsin for the treatment of T-cell lymphoma (launched in 2009, originally developed by Celgene Corporation in the United States), belinostat for the treatment of relapsed or resistant peripheral T-cell lymphoma (launched in 2014, originally developed by Spectrum Biopharmaceuticals), and panobinostat for the treatment of multiple myeloma (launched in 2015, originally developed by Novartis in Switzerland). In 2015, Shenzhen Microchip successfully launched chidamide, the first HDAC inhibitor for the treatment of lymphoma on the Chinese market, leveraging the domestic Chinese market. An increasing number of HDACi are entering clinical practice for the treatment and adjuvant treatment of solid tumors such as colon cancer and lung cancer, as well as hematologic malignancies such as leukemia and lymphoma.
[0006] Summary of the Invention
[0007] One of the objectives of the present invention is to provide a novel indazole-containing hydroxamic acid derivative that can simultaneously exert a good inhibitory effect on multiple targets (especially histone deacetylase 1, histone deacetylase 6, and two tyrosine kinases (vascular endothelial growth factor receptor and platelet-derived growth factor receptor)).
[0008] Another object of the present invention is to provide a pharmaceutical composition comprising the novel indazole-containing hydroxamic acid derivative.
[0009] Another object of the present invention is to provide the use of the novel indazole-containing hydroxamic acid derivative or the pharmaceutical composition comprising the novel indazole-containing hydroxamic acid derivative in the preparation of a drug for preventing and / or treating diseases mediated by tyrosine kinase and / or histone deacetylase.
[0010] In order to achieve the above object, a technical solution adopted by the present invention is:
[0011] A compound represented by general formula (I), a pharmaceutically acceptable salt, hydrate or prodrug thereof,
[0012] Where: R a 、R b are independently selected from hydrogen, C 1-20 alkyl, 3-10 membered heterocycloalkyl, 5-12 membered aromatic group, 5-12 membered heteroaryl group; wherein, the C 1-20 The alkyl, 3-10 membered heterocycloalkyl, 5-12 membered aromatic, and 5-12 membered heteroaryl groups are each independently unsubstituted or substituted by one, two, three or more substituents selected from the group consisting of fluorine, chlorine, bromine, iodine, nitro, cyano, mercapto, hydroxyl, amino, C 1-6 Alkyl-substituted amino, C 1-10 Alkyl, halogenated C1-6 Alkyl, nitro substituted C 1-6 Alkyl, cyano substituted C 1-6 Alkyl, mercapto substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, nitro substituted C 1-6 Alkoxy, cyano substituted C 1-6 Alkoxy, mercapto substituted C 1-6 Alkoxy, amino substituted C 1-6 Alkoxy, hydroxy substituted C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, -C(=O)R1, -C(=O)NHR2, -C(=O)OR3, -NHC(=O)R4, -OC(=O)R5;
[0013] R1, R2, R3, R4, R5 are independently selected from unsubstituted C 1-20 Alkyl, or C substituted by one or more substituents independently selected from fluorine, chlorine, bromine, iodine, nitro, cyano, mercapto, hydroxyl, amino 1-20 alkyl;
[0014] Each R c are the same or different and are each independently selected from hydrogen, C 1-20 Alkyl, C 1-20 Alkoxy, fluorine, chlorine, bromine, iodine, nitro, cyano, mercapto, hydroxyl, amino, C 1-6 Alkyl-substituted amino, halogenated C 1-6 Alkyl, nitro substituted C 1-6 Alkyl, cyano substituted C 1-6 Alkyl, mercapto substituted C 1-6 Alkyl, amino substituted C 1-6 alkyl;
[0015] R d 、R e are independently selected from hydrogen, C 1-20 Alkyl, nitro substituted C 1-6 Alkyl, cyano substituted C 1-6 Alkyl, mercapto substituted C 1-6 Alkyl, amino substituted C 1-6 alkyl;
[0016] R g Having a chain structure, the number of atoms constituting the main chain of the chain structure is 3-15 and the number of heteroatoms is no more than 2, and the heteroatoms are selected from oxygen, sulfur, and nitrogen;
[0017] x is 1, 2, 3, or 4.
[0018] In some embodiments, C 1-20 The alkyl group can be C 1-10 Alkyl or C 10-20 Alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, hexyl, heptyl, and the like.
[0019] According to some preferred aspects of the present invention, the number of heteroatoms in the atoms constituting the main chain of the chain structure is 1 or 2, and one of the heteroatoms is aligned with the indazole ring. The benzene rings are connected.
[0020] According to some preferred aspects of the present invention, the chain structure is a saturated straight chain or a saturated branched chain.
[0021] According to some preferred and specific aspects of the present invention, the compound has a structure shown in general formula (II):
[0022] Where: R a 、R b 、R c 、R d 、R e , x are respectively the same as R in the general formula (Ⅰ) a 、R b 、R c 、R d 、R e , x are the same, A, B are independently CH2, O, S or -N(R6)-, R6 is hydrogen or C 1-6 Alkyl, m and n are independently selected from integers of 0-10, and 3≤m+n≤10.
[0023] In some embodiments, m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. In some embodiments, n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10.
[0024] According to some preferred aspects of the present invention, when any of the following situations exists, B is CH2:
[0025] (1) A is CH2; (2) A is selected from O, S or -N(R6)-, and m is 0; (3) n is 0.
[0026] According to some preferred aspects of the present invention, A is selected from CH2, O, S or -NH-, and B is selected from CH2, O, -N(CH3)-, -N(CH2CH3)- or -N(CH2CH2CH3)-.
[0027] In some embodiments of the present invention, A is O, B is CH2, and m+n is 3, 4 or 5.
[0028] According to some preferred aspects of the present invention, R a 、R b Not hydrogen at the same time.
[0029] Furthermore, R a 、R b wherein one is selected from unsubstituted or substituted pyrimidinyl, pyrazolyl, pyridinyl, pyrazinyl, imidazolyl, pyridazinyl, thiazolyl, phenyl; the other is selected from hydrogen, or C 1-6 Alkyl. The substituents used include: fluorine, chlorine, bromine, iodine, nitro, cyano, mercapto, hydroxyl, amino, C 1-6 Alkyl-substituted amino, C 1-10 Alkyl, halogenated C 1-6 Alkyl, nitro substituted C 1-6 Alkyl, cyano substituted C 1-6 Alkyl, mercapto substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, nitro substituted C 1-6 Alkoxy, cyano substituted C 1-6 Alkoxy, mercapto substituted C 1-6 Alkoxy, amino substituted C 1-6 Alkoxy, hydroxy substituted C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, -C(=O)R1, -C(=O)NHR2, -C(=O)OR3, -NHC(=O)R4, -OC(=O)R5; R1, R2, R3, R4, R5 are independently selected from unsubstituted C 1-20 Alkyl, or C substituted by one or more substituents independently selected from fluorine, chlorine, bromine, iodine, nitro, cyano, mercapto, hydroxyl, amino 1-20 alkyl.
[0030] In some embodiments, the compound has a structure represented by formula (III):
[0031] Where: R c 、R d 、R e , x, A, B, m, n are respectively the same as R in the general formula (I I) c 、R d 、Re , x, A, B, m, n are the same; R b is selected from hydrogen, or is selected from C 1-6 Alkyl; R7 is selected from fluorine, chlorine, bromine, iodine, hydroxyl, mercapto, cyano, amino, methylamino, ethylamino, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, hydroxymethyl, mercaptomethyl, C(=O)CH3, C(=O)CH2CH3, C(=O)NHCH3, C(=O)NHCH2CH3, NHC(=O)CH3, NHC(=O)CH2CH3, NHCH3, N(CH3)2, NHCH2CH3, t is 0, 1, 2, 3, 4 or 5, D and E are independently selected from CH or N.
[0032] In some embodiments, when t is 4, at least one of D and E is CH, and when t is 5, both D and E are CH.
[0033] In some embodiments, the compound has a structure represented by formula (IV):
[0034] Where: R b 、R c 、R d 、R e , x, A, B, m, n are respectively the same as R in the general formula (III) b 、R c 、R d 、R e , x, A, B, m, and n are the same, and R8 and R9 are independently selected from hydrogen, fluorine, chlorine, bromine, iodine, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, halogenated methyl, halogenated ethyl, halogenated n-propyl, halogenated isopropyl, halogenated n-butyl, halogenated isobutyl, methoxy, ethoxy, halogenated methoxy, and halogenated ethoxy.
[0035] In the present invention, the halogenated group may be substituted with one or more halogens selected from fluorine, chlorine, bromine, and iodine, for example, 1 fluorine, 2 fluorines, 1 chlorine and 1 fluorine, 2 bromines and 1 fluorine, etc.
[0036] In some embodiments, R b 、R d 、R e are independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl or isobutyl.
[0037] In some embodiments, each R care the same or different and are each independently selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, methoxy or ethoxy.
[0038] In some embodiments, R b 、R c 、R d 、R e All are hydrogen.
[0039] In some embodiments, R g Selected from:
[0040] In some embodiments, the compound has a structure represented by formula (V):
[0041] wherein: p is 2, 3, 4, 5, 6, 7, 8, 9 or 10, and R8 and R9 are independently selected from hydrogen, fluorine, chlorine, bromine, iodine, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, halogenated methyl, halogenated ethyl, halogenated n-propyl, halogenated isopropyl, halogenated n-butyl, halogenated isobutyl, methoxy, ethoxy, halogenated methoxy, and halogenated ethoxy.
[0042] In some embodiments of the present invention, the structural formula of the compound is as shown in any one of formulas (ST-01) to (ST-16):
[0043] Another technical solution provided by the present invention is a pharmaceutical composition comprising the above-mentioned compound, a pharmaceutically acceptable salt, hydrate or prodrug thereof, and a pharmaceutically acceptable carrier.
[0044] Furthermore, the pharmaceutical composition may further comprise a diluent or an excipient.
[0045] Furthermore, the pharmaceutical composition is a composition for preventing and / or treating malignant tumors, including but not limited to renal cancer, liver cancer, colon cancer, gastrointestinal stromal tumors, lung cancer, breast cancer, pancreatic cancer, glioma, lymphoma, fibrosarcoma, ovarian cancer, prostate cancer, leukemia, and lymphoma.
[0046] Another technical solution provided by the present invention is: use of the above-mentioned compound, its pharmaceutically acceptable salt, hydrate or prodrug, or the above-mentioned pharmaceutical composition in the preparation of a drug for preventing and / or treating diseases mediated by tyrosine kinase and / or histone deacetylase.
[0047] Furthermore, the disease mediated by tyrosine kinase and / or histone deacetylase is a malignant tumor, and the malignant tumor includes but is not limited to renal cancer, liver cancer, colon cancer, gastrointestinal stromal tumor, lung cancer, breast cancer, pancreatic cancer, glioma, lymphoma, fibrosarcoma, ovarian cancer, prostate cancer, leukemia, and lymphoma.
[0048] According to the present invention, the compound includes not only a single compound form, but also a mixture of multiple compounds whose structures meet the requirements of general formula (I), as well as different isomeric forms of the same compound such as racemates, enantiomers, diastereomers, etc.
[0049] The pharmaceutically acceptable salts include, but are not limited to, hydrochloride, hydrobromide, phosphate, sulfate, acetate, trifluoroacetate, maleate, methanesulfonate, benzenesulfonate, benzoate, toluenesulfonate, succinate, fumarate, tartrate, gallate, citrate, and the like.
[0050] The compound represented by general formula (I) or a pharmaceutically acceptable salt thereof is usually administered orally in the form of a pharmaceutical preparation comprising the active ingredient or a pharmaceutically acceptable salt or solvate thereof, or a solvate of such a salt, in a pharmaceutically acceptable dosage form. Depending on the disorder to be treated and the patient, the composition can be administered at different doses.
[0051] The pharmaceutical formulations of the compounds represented by general formula (I) described above can be prepared for oral administration, particularly in the form of tablets or capsules, and particularly involve techniques aimed at providing colon-targeted drug release.
[0052] The pharmaceutical formulations of the compounds of formula (I) described above may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy.
[0053] Pharmaceutical formulations suitable for oral administration can include one or more physiologically compatible carriers and / or excipients, and can be in the form of solid or liquid. Tablets and capsules can be prepared with adhesives, fillers, lubricants and / or surfactants (such as sodium lauryl sulfate). Liquid compositions can contain conventional additives, such as suspending agents, emulsifiers and / or preservatives. Liquid compositions can be encapsulated in, for example, gelatin to provide unit dosage forms.
[0054] Oral formulations are preferred, particularly tablets or capsules, which can be formulated by methods known to those skilled in the art to provide a dose of the active compound in the range of 0.001 mg to 10,000 mg, for example, a dose in the range of 0.01 mg to 5,000 mg, or a dose in the range of 0.1 mg to 1,000 mg, etc.
[0055] In the present invention, the prodrug of the compound represented by general formula (I) refers to a prodrug that can be converted into at least one compound of general formula (I) or its salt by metabolism or chemical reaction (such as enzymatic hydrolysis or hydrolysis) in the subject after being administered by an appropriate method.
[0056] Another technical solution provided by the present invention is an intermediate for preparing the above-mentioned compound, its pharmaceutically acceptable salt, hydrate or prodrug, wherein the intermediate has a structure represented by the general formula (VI):
[0057] Where: R a 、R b 、R c 、R d 、R e 、R g , x are respectively the same as R in the above general formula a 、R b 、R c 、R d 、R e 、R g , x are the same, R is C 1-6 Alkoxy.
[0058] In some embodiments, R may be methoxy, ethoxy, propoxy, or tert-butoxy.
[0059] Another technical solution provided by the present invention is a method for preparing the above-mentioned compound, its pharmaceutically acceptable salt, hydrate or prodrug, which comprises the step of reacting the above-mentioned intermediate with hydroxylamine.
[0060] In some embodiments, the hydroxylamine is prepared by adding a hydroxylamine inorganic acid salt, and the hydroxylamine inorganic acid salt includes but is not limited to hydroxylamine hydrochloride and / or hydroxylamine phosphate.
[0061] In some embodiments, the reaction of the intermediate with hydroxylamine is carried out under alkaline conditions in an alcohol solvent. In some embodiments, the alkaline conditions are formed by adding an alkaline substance, including but not limited to sodium hydroxide, potassium hydroxide, etc.
[0062] In some embodiments, the alcohol solvent includes but is not limited to methanol.
[0063] Due to the application of the above technical solution, the present invention has the following advantages compared with the prior art:
[0064] The compounds of the present invention can combine multiple important targets into one, and in particular, can simultaneously exhibit strong inhibitory effects on histone deacetylase VI (HDAC6, histone deacetylases 6), histone deacetylase 1 (HDAC1), two tyrosine kinases (vascular endothelial growth factor receptor, Vascular endothelial cell growth factor 2, VEGFR2), and platelet-derived growth factor receptor (platelet-derived growth factor-β, PDGFR-β). These compounds can effectively avoid problems that may arise from the different properties and metabolism of multiple drugs when used in combination, can fully exert synergistic effects to increase biological activity, and have good application prospects. DETAILED DESCRIPTION
[0065] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below.
[0066] The term "C 1-20 "Alkyl" refers to a straight or branched chain saturated hydrocarbon group of 1 to 20 carbon atoms ("C1-C20-alkyl"). In some embodiments, the alkyl group contains 1 to 10 carbon atoms, or 1 to 6 carbon atoms, such as 1, 2, 3, 4, 5, or 6 carbon atoms. Some non-limiting examples include methyl, ethyl, propyl, 2-propyl (isopropyl), n-butyl, isobutyl, sec-butyl, tert-butyl, and 2,2-dimethylpropyl.
[0067] The term "alkoxy" refers to an alkyl group attached to the parent molecular moiety through an oxygen atom. In some embodiments, the alkoxy group contains 1 to 6 carbon atoms and can be represented by C 1-6 Alkoxy. Some non-limiting examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, and tert-butoxy.
[0068] The term "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br) or iodine (I). Preferably, the term "halogen" refers to fluorine (F), chlorine (Cl) or bromine (Br).
[0069] The term "amino-substituted alkyl" refers to an alkyl group in which at least one hydrogen atom of the alkyl group is replaced by an amino group. 1-6Alkyl refers to C 1-6 At least one hydrogen atom of the alkyl group is replaced by an amino group. Preferably, "aminoalkyl" refers to an alkyl group in which 1, 2 or 3 hydrogen atoms of the alkyl group are replaced by an amino group. Non-limiting examples of aminoalkyl groups can be aminomethyl and 1-aminoethyl etc.
[0070] The term "amino-substituted alkoxy" refers to an alkoxy group in which at least one hydrogen atom of the alkoxy group is replaced by an amino group. 1-6 Alkoxy refers to C 1-6 At least one hydrogen atom of the alkoxy group is replaced by an amino group. Preferably, "aminoalkoxy" refers to an alkoxy group in which 1, 2 or 3 hydrogen atoms of the alkoxy group are replaced by an amino group. Non-limiting examples of aminoalkoxy groups are aminomethoxy and 1-aminoethoxy.
[0071] The term "nitro-substituted alkyl" refers to an alkyl group wherein at least one hydrogen atom of the alkyl group is replaced by a nitro group. For example, a nitro-substituted C 1-6 Alkyl refers to C 1-6 At least one hydrogen atom of the alkyl group is replaced by a nitro group.
[0072] The term "nitro-substituted alkoxy" refers to an alkoxy group wherein at least one hydrogen atom of the alkoxy group is replaced by a nitro group. For example, a nitro-substituted C 1-6 Alkoxy refers to C 1-6 At least one hydrogen atom of the alkoxy group is replaced by a nitro group.
[0073] The term "cyano-substituted alkyl" refers to an alkyl group in which at least one hydrogen atom of the alkyl group is replaced by a cyano group. 1-6 Alkyl refers to C 1-6 At least one hydrogen atom of the alkyl group is replaced by a cyano group.
[0074] The term "cyano-substituted alkoxy" refers to an alkoxy group in which at least one hydrogen atom of the alkoxy group is replaced by a cyano group. 1-6 Alkoxy refers to C 1-6 At least one hydrogen atom of the alkoxy group is replaced by a cyano group.
[0075] The term "mercapto-substituted alkyl" refers to an alkyl group wherein at least one hydrogen atom of the alkyl group is substituted with a mercapto group. 1-6 Alkyl refers to C 1-6 At least one hydrogen atom of the alkyl group is replaced by a mercapto group.
[0076] The term "mercapto-substituted alkoxy" refers to an alkoxy group wherein at least one hydrogen atom of the alkoxy group is replaced by a mercapto group. For example, a mercapto-substituted C 1-6 Alkoxy refers to C 1-6 At least one hydrogen atom of the alkoxy group is replaced by a mercapto group.
[0077] The term "hydroxy-substituted alkyl" refers to an alkyl group wherein at least one hydrogen atom of the alkyl group is replaced by a hydroxy group. For example, a hydroxy-substituted C 1-6 Alkyl refers to C 1-6 At least one hydrogen atom of the alkyl group is replaced by a hydroxy group.
[0078] The term "hydroxy-substituted alkoxy" refers to an alkoxy group in which at least one hydrogen atom of the alkoxy group is replaced by a hydroxy group. For example, a hydroxy-substituted C 1-6 Alkoxy refers to C 1-6 At least one hydrogen atom of the alkoxy group is replaced by a hydroxy group.
[0079] The term "halogenated alkyl" refers to an alkyl group in which at least one hydrogen atom of the alkyl group is replaced by a halogen such as fluorine (F), chlorine (Cl), bromine (Br) or iodine (I). 1-6 Alkyl refers to C 1-6 At least one hydrogen atom of the alkyl group is replaced by a halogen.
[0080] The term "halogenated alkoxy" refers to an alkoxy group in which at least one hydrogen atom of the alkoxy group is replaced by a halogen such as fluorine (F), chlorine (Cl), bromine (Br) or iodine (I). 1-6 Alkoxy refers to C 1-6 At least one hydrogen atom of the alkoxy group is replaced by halogen.
[0081] The term "heterocycloalkyl" refers to a saturated monocyclic, bicyclic, or multicyclic ring with more rings fused together. For example, "3-10 membered heterocycloalkyl" refers to a monocyclic, bicyclic, or multicyclic ring with more rings fused together having 3 to 10 ring atoms, wherein 1, 2, 3 or 4 of the ring atoms are heteroatoms selected from N, O and S, and the remaining ring atoms are carbon. Some non-limiting examples of heterocycloalkyl include azetidin-3-yl, azetidin-2-yl, oxetan-3-yl, oxetan-2-yl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, pyrrolidinyl (e.g., pyrrolidin-2-yl), morpholino, morpholin-2-yl, morpholin-3-yl, pyrrolidinyl (e.g., pyrrolidin-3-yl), piperazinyl (e.g., piperazin-1-yl), 3-azabicyclo[3.1.0]hexan-6-yl, or 2,5-diazabicyclo[2.2.1]heptan-2-yl.
[0082] The term "aromatic group" refers to an all-carbon monocyclic or fused polycyclic (i.e., rings that share adjacent pairs of carbon atoms) group with a conjugated π electron system. It is an aromatic cyclic group. When the aromatic group is preceded by a ring atom number specification, such as a 5-12-membered aromatic group, it means that the aromatic group has 5-12 ring atoms. Representative examples of aromatic groups include, but are not limited to, phenyl, naphthyl, and similar groups.
[0083] The term "heteroaryl" refers to an aromatic heterocyclic group having one to multiple (preferably 1, 2, 3, 4, or 5) heteroatoms, which may be a monocyclic (monocyclic) or polycyclic (bicyclic, tricyclic, or polycyclic) group fused together or covalently linked, each heterocyclic group containing a heteroatom may have one or more (e.g., 1, 2, 3, or 4) heteroatoms independently selected from the group consisting of oxygen, sulfur, and nitrogen. When the number of atoms in the heteroaryl group is specified, it refers to the number of ring atoms in the heteroaryl group. For example, a 5-12-membered heteroaryl group refers to a heteroaryl group having 5-12 ring atoms. Representative examples of heteroaryl groups include, but are not limited to, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, furanyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazolyl, tetrazolyl, 1H-pyrazolo[3,4-d]pyrimidin-6-yl, or similar groups.
[0084] The term "hydroxy" refers to a -OH group.
[0085] The term "amino" refers to a -NH2 group.
[0086] The term "cyano" refers to a -CN (nitrile) group.
[0087] The term "nitro" refers to the group -NO2.
[0088] The term "mercapto" refers to the group -SH.
[0089] The term "pharmaceutically acceptable salt" refers to those salts that retain the biological effects and properties of free alkali or free acids, which are formed with inorganic acids (such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc., particularly hydrochloric acid) and organic acids (such as acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, lactic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcysteine, etc.). In addition, these salts can be prepared by adding inorganic or organic bases to the free acids. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium salts, etc. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyimine resins, and the like.
[0090] The term "hydrate" refers to an association between a solvent molecule being water and a compound of the present invention formed by one, two, three or more water molecules.
[0091] As used herein, the term "treating" includes: (1) inhibiting a state, disorder, or condition of at least one clinical or subclinical symptom of a disease (e.g., in the case of maintenance therapy, arresting, alleviating, or delaying the progression of the disease or its recurrence); and / or (2) relieving a condition (i.e., causing the state, disorder, or condition of the disease or at least one clinical or subclinical symptom to resolve). The benefit to the patient being treated is statistically significant or at least perceptible to the patient or physician. However, it should be understood that when a drug is administered to a patient to treat a disease, the result may not always be an effective treatment.
[0092] When indicating the number of substituents, the term "one or more" refers to a range from one substituent to the highest possible number of substituents, i.e., replacement of one hydrogen by a substituent until all hydrogens are replaced by substituents, for example, "one or more" can refer to one, two, three, four, five or six, etc.
[0093] The terms "pharmaceutical composition" and "pharmaceutical formulation" (or "formulation") are used interchangeably and refer to a mixture or solution comprising a therapeutically effective amount of an active pharmaceutical ingredient and a pharmaceutically acceptable excipient, which is administered to a mammal, eg, a human in need thereof.
[0094] The terms "excipient," "pharmaceutically acceptable carrier," and "therapeutically inert excipient" are used interchangeably and refer to any pharmaceutically acceptable ingredient in a pharmaceutical composition that is not therapeutically active and is non-toxic to the subject to which it is administered, such as a disintegrant, binder, filler, solvent, buffer, tonicity agent, stabilizer, antioxidant, surfactant, carrier, diluent, or lubricant used to formulate the drug product.
[0095] The above scheme is further described below in conjunction with specific examples; it should be understood that these examples are used to illustrate the basic principles, main features and advantages of the present invention, and the present invention is not limited to the scope of the following examples; the implementation conditions adopted in the examples can be further adjusted according to specific requirements, and the implementation conditions not specified are generally the conditions in routine experiments.
[0096] Unless otherwise specified in the following examples, all raw materials were purchased from commercial sources or prepared by conventional methods in the art.
[0097] Example 1 Synthesis of Compound ST-01
[0098] Experimental process:
[0099] 1) Preparation of Compound 2
[0100] Compound 1 (11.6 g, 46.03 mmol) was dissolved in 100 ml of anhydrous tetrahydrofuran at -78°C, and lithium diisopropylamide (30 ml, 59.83 mmol, 2 mol / L tetrahydrofuran solution) was added. After stirring at -78°C for 1 hour, carbon dioxide was bubbled into the reaction and stirring was continued for 1 hour. The reaction mixture was then adjusted to pH 2 with 6M hydrochloric acid, extracted with ethyl acetate, washed with brine, and the organic phase dried over anhydrous sodium sulfate and concentrated in vacuo to give 14.8 g of crude compound 2 as a yellow solid, which was used directly in the next reaction. 1 H NMR (400MHz, DMSO-d6) δ13.92(s,1H),7.62(dd,J=8.6,1.5Hz,1H),7.05(t,J=8.8Hz,1H),3.85(s,3H).
[0101] 2) Preparation of Compound 3
[0102] Compound 2 (16.6 g, 56.07 mmol) and dimethylformamide (0.3 ml) were added to 50 ml of thionyl chloride and heated at 80°C for 3 hours. The reaction mixture was concentrated in vacuo to give a crude product, 2-fluoro-6-iodo-3-methoxybenzoyl chloride. 50 ml of anhydrous tetrahydrofuran and 50 ml of aqueous ammonia were added to the crude product at 0°C, and stirring was continued at 0°C for 0.5 hours. The reaction mixture was concentrated in vacuo to give 10.0 g of crude compound 3 as a brown solid, which was used directly in the next reaction. 1 H NMR (400MHz, DMSO-d6) δ7.99(s,1H),7.73(s,1H),7.57(dd,J=8.8,1.4Hz,1H),6.99(t,J=8.8Hz,1H),3.84(s,3H).
[0103] 3) Preparation of Compound 4
[0104] Compound 3 (10.7 g, 36.27 mmol) and thionyl chloride (22.0 g, 181.33 mmol) were added to 60 ml of dimethylformamide and heated to 115 ° C for overnight reaction. The reaction mixture was poured into cooling water and extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate aqueous solution and brine, dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (petroleum ether-ethyl acetate, 10:1) to obtain 4.4 g of red solid compound 4 with a yield of 43.8%. 1 H NMR (400MHz, DMSO-d6) δ7.80 (dd, J=8.8, 1.3Hz, 1H), 7.36 (t, J=8.8Hz, 1H), 3.89 (s, 3H).
[0105] 4) Preparation of Compound 5
[0106] Compound 4 (1.0 g, 3.61 mmol) was dissolved in 10 ml of dichloromethane at -78 ° C, and 22 ml of boron tribromide was added. The reaction mixture was placed at room temperature and stirred overnight. The reaction mixture was then poured into cold water and extracted with dimethylformamide. The organic layer was washed with brine, dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (petroleum ether-ethyl acetate, 7:1) to obtain 850 mg of brown solid compound 5 with a yield of 89.5%. 1 H NMR (400MHz, DMSO-d6) δ10.96(s,1H),7.62(dd,J=8.8,1.2Hz,1H),7.09(t,J=8.8Hz,1H).
[0107] 5) Preparation of Compound 7
[0108] Compound 5 (1.0 g, 3.80 mmol) was dissolved in 10 ml of acetonitrile, and compound 6 (1.0 g, 4.56 mmol) and potassium carbonate (1.6 g, 11.41 mmol) were added. The reaction mixture was heated at 60°C for 6 hours and then concentrated in vacuo. The residue was purified by silica gel column chromatography (petroleum ether-ethyl acetate, 5:1) to obtain 1.5 g of compound 7 as a yellow solid in a yield of 97.4%. 1 H NMR (400MHz, DMSO-d6) δ7.76(dd,J=8.8,1.3Hz,1H),7.36(t,J=8.8Hz,1H),4.09(t,J=6.4Hz,2H),3.58(s, 3H),2.30(t,J=7.2Hz,2H),1.76–1.67(m,2H),1.58–1.49(m,2H),1.44–1.28(m,4H).LC-MS:(ESI)m / z[M+H] + =406.0
[0109] 6) Preparation of Compound 8
[0110] Compound 7 (1.0 g, 2.47 mmol) and hydrazine hydrate (927 mg, 18.51 mmol) were added to 10 mL of n-butanol and heated at 110° C. for 1 hour. The reaction mixture was then concentrated in vacuo and purified by silica gel column chromatography (dichloromethane-methanol, 30:1) to afford 508 mg of compound 8 as a yellow solid in a 49.3% yield. 1 H NMR (400MHz, DMSO-d6) δ11.91(s,1H),7.19(d,J=7.6Hz,1H),6.50(d,J=7.6Hz,1H),4.97(s,2H),4.06(t,J=6.4Hz,2H),3.58(s,3H),2.31 (t,J=7.2Hz,2H),1.80–1.70(m,2H),1.55(dt,J=15.2,7.2Hz,2H),1.46(dd,J=15.2,7.2Hz,2H),1.38–1.29(m,2H).LC-MS: (ESI)m / z[M+H] + =418.0
[0111] 7) Preparation of Compound 10
[0112] Compound 8 (1.1 g, 2.64 mmol) was dissolved in a mixed solution of 12 ml of dimethyl ether and 4 ml of water, and compound 9 (1.2 g, 5.27 mmol), tetrakis(triphenylphosphine)palladium (305 mg, 0.26 mmol) and sodium carbonate (838 mg, 7.91 mmol) were added. The reaction mixture was purged with nitrogen and heated to 80°C for overnight reaction. The reaction mixture was then concentrated in vacuo and purified by silica gel column chromatography (dichloromethane-methanol, 15:1) to give 868 mg of brown solid compound 10 in a yield of 86.1%. 1 H NMR (400MHz, DMSO-d6) δ11.70(s,1H),7.07(d,J=8.4Hz,2H),6.70(d,J=7.6Hz,1H),6. 65(d,J=8.4Hz,2H),6.57(d,J=7.6Hz,1H),5.19(s,2H),4.31(s,2H),4.09(t,J=6.4Hz ,2H),3.58(s,3H),2.33(t,J=7.2Hz,2H),1.82–1.73(m,2H),1.57(dt,J=14.8,7.2Hz, 2H),1.49(dd,J=15.2,7.6Hz,2H),1.36(dd,J=14.8,8.0Hz,2H).LC-MS:(ESI)m / z[M+H] + =383.2
[0113] 8) Preparation of Compound 12
[0114] Compound 10 (860 mg, 2.25 mmol) was dissolved in 8 mL of dimethylformamide at 0°C, and compound 11 (299 mg, 2.25 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was then concentrated in vacuo and purified by silica gel column chromatography (dichloromethane-methanol, 20:1) to obtain 680 mg of compound 12 as a yellow solid in a yield of 58.7%. 1H NMR (400MHz, DMSO-d6) δ11.81(s,1H),8.75(s,1H),8.63(s,1H),7.55(d,J=8.4Hz,2H),7.34(d,J=8.4Hz,2H ),7.32(s,1H),7.25(d,J=8.4Hz,1H),7.16(t,J=7.6Hz,1H),6.80(d,J=7.2Hz,1H),6.76(d,J=7.6Hz,1H),6 .67(d,J=7.6Hz,1H),4.30(s,2H),4.12(t,J=6.4Hz,2H),3.58(s,3H),2.33(t,J=7.6Hz,2H),2.29(s,3H),1 .84–1.74(m,2H),1.59(dd,J=15.0,7.6Hz,2H),1.54–1.46(m,2H),1.40–1.31(m,2H).LC-MS:(ESI)m / z[M+H] + =516.2
[0115] 9) Preparation of compound ST-01
[0116] 4.2 g of hydroxylamine hydrochloride and 2.4 g of sodium hydroxide were added to 25 ml of methanol and stirred at 0°C for half an hour. The reaction mixture was filtered to obtain a filtrate. Compound 12 (1.5 g, 2.91 mmol) and sodium hydroxide (465 mg, 11.64 mmol) were added to 15 ml of the above filtrate and stirred at room temperature for 2 hours. The pH value of the reaction mixture was then adjusted to 7 with 1 mol of hydrochloric acid. The reaction mixture was filtered to obtain a solid, which was washed with methanol and water to give 1.0 g of white solid compound ST-01 in a yield of 66.5%. 1 H NMR (400MHz, DMSO-d6) δ11.83(s,1H),10.38(s,1H),8.80–8.62(m,3H),7.57(d,J=8.0Hz, 2H),7.39–7.31(m,3H),7.27(d,J=8.0Hz,1H),7.17(t,J=7.6Hz,1H),6.80(d,J=7.2Hz,1H ),6.75(d,J=7.6Hz,1H),6.68(d,J=7.6Hz,1H),4.32(s,2H),4.11(t,J=6.0Hz,2H),2.29( s,3H),1.99(t,J=7.2Hz,2H),1.83–1.75(m,2H),1.58–1.47(m,4H),1.34(d,J=6.8Hz,2H). 13C NMR(101MHz,DMSO-d6)δ169.7,153.0,148.9,143.9,140.1,139.3,138.5,134.2,133.2,129.7,129.1,127.9,12 3.1,120.0,119.2,118.5,115.9,112.3,106.4,68.2,32.7,29.1,28.9,25.6,25.6,21.7.LC-MS: (ESI)m / z[M+H] + =517.2
[0117] Example 2 Synthesis of Compound ST-04
[0118] Experimental process:
[0119] 1) Compound 10 was prepared using the method in Example 1
[0120] 2) Preparation of Compound 12
[0121] Compound 10 (1.0 g, 2.61 mmol) was dissolved in 10 ml of dimethylformamide at 0°C, and then compound 11 (394 mg, 2.61 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was then concentrated in vacuo and purified by silica gel column chromatography (dichloromethane-methanol, 20:1) to obtain 560 mg of compound 12 as a white solid in a yield of 40.1%. 1 H NMR (400MHz, DMSO-d6) δ11.81(s,1H),9.17(s,1H),8.52(s,1H),8.01(d,J=7.7Hz,1H),7.56(d,J=8.6Hz,2H),7.36 (d,J=8.5Hz,2H),7.11(dd,J=11.3,8.3Hz,1H),6.83–6.78(m,1H),6.76(d,J=7 .8Hz,1H),6.67(d,J=7.6Hz,1H),4.29(s,2H),4.12(t,J=6.4Hz,2H),3.58(s,3H ),2.33(t,J=7.4Hz,2H),2.28(s,3H),1.85–1.75(m,2H),1.59(dd,J=15.1,7.5 Hz,2H),1.50(dd,J=15.6,7.5Hz,2H),1.41–1.32(m,2H).LC-MS:(ESI)m / z[M+H] + =534.2
[0122] 3) Preparation of Compound ST-04 and ST-04 Hydrochloride
[0123] 4.2 g of hydroxylamine hydrochloride and 2.4 g of sodium hydroxide were added to 25 ml of methanol and stirred at 0°C for half an hour. The reaction mixture was filtered to obtain a filtrate. Compound 12 (760 mg, 1.42 mmol) and sodium hydroxide (227 mg, 5.68 mmol) were added to 10 ml of the above filtrate and stirred at room temperature for 2 hours. The pH value of the reaction mixture was then adjusted to 7 with 1 mol of hydrochloric acid. The reaction mixture was filtered to obtain a solid. The solid was washed with methanol and water to obtain 400 mg of white solid compound ST-04 with a yield of 52.5%. 990 mg of compound ST-04 was then added to water and heated at 80°C for half an hour. The reaction mixture was cooled to room temperature and filtered to obtain a solid. The above solid was added to 30 ml of 2 mol of hydrochloric acid, stirred at room temperature for 1 hour, and freeze-dried to obtain 760 mg of compound ST-04 hydrochloride (containing one molecule of hydrochloric acid).
[0124] Compound ST-04: 1 H NMR (400MHz, DMSO-d6) δ11.81(s,1H),10.34(s,1H),9.21(s,1H),8.65(s,1H),8.54(d,J=2.1Hz,1H) ,8.01(d,J=6.4Hz,1H),7.56(d,J=8.5Hz,2H),7.36(d,J=8.4Hz,2H),7.11(dd,J=11.3,8.4Hz,1H),6. 83–6.78(m,1H),6.76(d,J=7.8Hz,1H),6.68(d,J=7.7Hz,1H),4.29(s,2H),4.12(t,J=6.3Hz,2H),2. 28(s,3H),1.97(t,J=7.3Hz,2H),1.84–1.73(m,2H),1.59–1.45(m,4H),1.34(dd,J=14.6,7.6Hz,2H).
[0125] Compound ST-04 hydrochloride:
[0126] 1H NMR(400MHz,DMSO-d6)δ13.26(br,1H),10.42(br,1H),9.79(s,1H),8.78(s,1H),7.98(dd, J=7.8,1.7Hz,1H),7.61(d,J=8.5Hz,2H),7.43(d,J=8.5Hz,2H),7.09(dd,J=11.2,8.3Hz,1H ),6.99(d,J=7.9Hz,1H),6.93(d,J=7.8Hz,1H),6.85–6.75(m,1H),4.18(t,J=6.2Hz,2H),2 .27(s,3H),1.98(t,J=7.3Hz,2H),1.86–1.73(m,2H),1.60–1.44(m,4H),1.36–1.29(m,2H). 19 F NMR(400MHz,DMSO-d6)δ-134.30. 13 C NMR(101MHz,DMSO-d6)δ169.6,152.8,152.0,149.7,144.1,139.7,134.7,133.9,133.9,132.1,129.7,127.6,127.5,12 3.2,122.9,121.6,118.6,115.1,114.9,112.7,108.5,68.6,32.7,28.9,28.8,25.6,25.6,21.2.LC-MS:(ESI)m / z[M+H] + =535.2.
[0127] Example 3 Synthesis of Compound ST-05
[0128] Experimental process:
[0129] 1) Preparation of Compound 2
[0130] At 0 ° C, compound 1 (5 g, 65.71 mmol) was dissolved in 200 ml of anhydrous tetrahydrofuran and sodium cyanide (2.89 g, 72.28 mmol) was added. After stirring at 0 ° C for 30 minutes, a solution of tert-butyldiphenylsilyl chloride (18.1 g, 65.71 mmol) dissolved in 50 ml of tetrahydrofuran was added. The reaction mixture was placed at room temperature and stirred overnight. The reaction mixture was then quenched with an aqueous ammonium chloride solution at 0 ° C and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography (petroleum ether-ethyl acetate, 10: 1) to give 13.6 g of colorless oily compound 2 in a yield of 65.8%. 1H NMR (400MHz, DMSO-d6) δ7.63(dd,J=7.4,1.6Hz,4H),7.50–7.38(m,6H),3.74(t,J=6.4Hz,2H),3.53(t,J=6.3Hz,2H),1.70(p,J=6.3Hz,2H),1.00(s,9H).
[0131] 2) Preparation of Compound 4
[0132] Compound 2 (13.6 g, 43.24 mmol) was dissolved in 170 ml of tert-butanol, and compound 3 (8.31 g, 64.86 mmol) and cesium carbonate (14.09 g, 43.24 mmol) were added. After stirring at room temperature for 6 hours, the reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography (petroleum ether-ethyl acetate, 10:1) to obtain 11.5 g of colorless oily compound 4 in a yield of 60%. 1 H NMR (400MHz, DMSO-d6) δ7.63–7.60(m,4H),7.49–7.38(m,6H),3.70(t,J=6.3Hz,2H),3.53(t,J=6.2H z,2H),3.48(t,J=6.2Hz,2H),2.38(t,J=6.2Hz,2H),1.74(p,J=6.2Hz,2H),1.36(s,9H),0.99(s,9H).
[0133] 3) Preparation of Compound 5
[0134] Compound 4 (0.5 g, 1.13 mmol) was dissolved in 5 ml of anhydrous tetrahydrofuran and tetrabutylammonium fluoride (2.30 ml, 2.26 mmol, 1 mol / L tetrahydrofuran solution) was added. The mixture was stirred at room temperature for 2 hours, and the reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo. The residue was purified by silica gel column chromatography (petroleum ether-ethyl acetate, 3:1) to give 180 mg of light yellow oily compound 5 in a yield of 78%. 1 H NMR (400MHz, DMSO-d6) δ4.34(t,J=5.1Hz,1H),3.53(t,J=6.2Hz,2H),3.41(t,J=6.8Hz,4H),2.39(t,J=6.2Hz,2H),1.68–1.56(m,2H),1.40(s,9H).
[0135] 4) Preparation of Compound 7
[0136] At 0 ° C, compound 6 (1.0 g, 3.80 mmol) was dissolved in 20 ml of anhydrous tetrahydrofuran, and compound 5 (853 mg, 4.18 mmol), triphenylphosphine (1.5 g, 5.7 mmol) and diethyl azodicarboxylate (1.54 g, 7.6 mmol) were added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was then concentrated in vacuo and purified by silica gel column chromatography (petroleum ether-ethyl acetate, 4:1) to give 1.0 g of yellow liquid compound 7 in a yield of 58.5%. 1 H NMR (400MHz, DMSO-d6) δ7.57(dd,J=8.8,1.7Hz,1H),6.96(t,J=8.6Hz,1H),4.13(t,J=6.3Hz,2H),3.67(t,J=6.3Hz, 2H), 3.61 (t, J=5.9Hz, 2H), 2.47 (dd, J=7.5, 5.0Hz, 2H), 2.06 (p, J=6.1Hz, 2H), 1.43 (s, 9H). LC-MS: (ESI) m / z [M+Na] + =472.0
[0137] 5) Preparation of Compound 8
[0138] Compound 7 (180 mg, 0.4 mmol) and hydrazine hydrate (140 mg, 2.8 mmol) were added to 6 ml of n-butanol, and the suspension was heated to 110° C. for 2 hours. The reaction mixture was then concentrated in vacuo and purified by silica gel column chromatography (dichloromethane-methanol, 30:1) to obtain 100 mg of yellow solid compound 8 in a yield of 54.1%. 1 H NMR (400MHz, CDCl3) δ7.28(d,J=8.0Hz,1H),6.42(d,J=8.0Hz,1H),4.18(t,J=6.2Hz,2H),3.69(t,J=6.3Hz, 2H),3.63(t,J=6.0Hz,2H),2.49(t,J=6.3Hz,2H),2.08(p,J=6.1Hz,2H),1.44(s,9H).LC-MS:(ESI)m / z[M+H] + =462.2
[0139] 6) Preparation of Compound 10
[0140] Compound 8 (1.4 g, 3.03 mmol) was dissolved in a mixture of 12 ml of dimethyl ether and 4 ml of water, and compound 9 (996 mg, 4.54 mmol), tetrakis(triphenylphosphine)palladium (350 mg, 0.3 mmol), and sodium carbonate (963 mg, 9.09 mmol) were added. The reaction mixture was heated to 80°C and reacted overnight under nitrogen. The reaction mixture was then concentrated in vacuo and purified by silica gel column chromatography (dichloromethane-methanol, 20:1) to obtain 1.2 g of brown solid compound 10, with a yield of 92.7%. 1 H NMR (400MHz, DMSO-d6) δ11.71(s,1H),7.07(d,J=8.4Hz,2H),6.69(d,J=7.7Hz,1H),6.65(d,J=8.4Hz,2H),6.57(d,J=7.7Hz,1H),5.19(s,2H),4 .31(s,2H),4.14(t,J=6.2Hz,2H),3.61(dt,J=9.2,6.2Hz,4H),2.43(t,J=6.1Hz,2H),1.99(p,J=6.1Hz,2H),1.37(s,9H).LC-MS: (ESI)m / z[M+H] + =427.2
[0141] 7) Preparation of Compound 12
[0142] Compound 10 (1.0 g, 2.34 mmol) was dissolved in 10 ml of dimethylformamide at 0°C, and compound 11 (354 mg, 2.34 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was then concentrated in vacuo and purified by silica gel column chromatography (dichloromethane-methanol, 20:1) to afford 760 mg of compound 12 as a white solid in a yield of 56.1%. 1H NMR (400MHz, DMSO-d6) δ11.84(s,1H),9.17(s,1H),8.52(d,J=2.5Hz,1H),8.01(dd,J=7.9,1.9Hz,1H),7.56(d,J=8.6Hz,2H),7.36( d,J=8.6Hz,2H),7.11(dd,J=11.4,8.3Hz,1H),6.84–6.78(m,1H),6.75(d,J=7.8Hz,1H),6.67(d,J=7.7Hz,1H),4.30(s,2H),4.17(t ,J=6.2Hz,2H),3.62(dt,J=12.2,6.2Hz,4H),2.44(t,J=6.1Hz,2H),2.28(s,3H),2.01(p,J=6.1Hz,2H),1.37(s,9H).4.31(s,2H),4 .14(t,J=6.2Hz,2H),3.61(dt,J=9.2,6.2Hz,4H),2.43(t,J=6.1Hz,2H),1.99(p,J=6.1Hz,2H),1.37(s,9H).LC-MS:(ESI)m / z[M+H] + =578.4
[0143] 8) Preparation of compound ST-05
[0144] 8.4 g of hydroxylamine hydrochloride and 4.8 g of sodium hydroxide were added to 50 ml of methanol, and the suspension was stirred at 0 ° C for half an hour. The reaction mixture was filtered to obtain a filtrate. Compound 12 (2.54 g, 4.40 mmol) and sodium hydroxide (704 mg, 17.6 mmol) were added to 30 ml of the above filtrate and stirred at 60 ° C for 2 hours. The pH value of the reaction mixture was then adjusted to 7 with 1 mol of hydrochloric acid. The reaction mixture was filtered to obtain a solid. The solid was washed with methanol and water to obtain 724 mg of white solid compound ST-05, with a yield of 31%. 1H NMR (400MHz, DMSO-d6) δ11.86(s,1H),10.43(s,1H),9.20(s,1H),8.79(s,1H),8.54(d,J=2.0Hz, 1H),8.03(d,J=6.4Hz,1H),7.57(d,J=8.4Hz,2H),7.37(d,J=8.4Hz,2H),7.12(dd,J=11.2,8.4Hz ,1H),6.79(dd,J=16.4,6.4Hz,2H),6.69(d,J=7.6Hz,1H),4.33(s,2H),4.18(t,J=6.0Hz,2H),3. 62(t,J=5.2Hz,4H),2.28(s,3H),2.22(t,J=6.0Hz,2H),2.06–1.96(m,2H).LC-MS:(ESI)m / z[M+H] + =537.2
[0145] Example 4 Synthesis of Compound ST-06
[0146] Experimental process:
[0147] 1) Preparation of Compound 3
[0148] At 0 ° C, compound 1 (6.0 g, 22.81 mmol) was dissolved in 60 ml of anhydrous tetrahydrofuran, and compound 2 (5.6 g, 25.09 mmol), triphenylphosphine (8.97 g, 34.21 mmol) and diethyl azodicarboxylate (9.22 g, 45.62 mmol) were added. The reaction mixture was placed at room temperature and stirred for 2 hours. The reaction mixture was then concentrated in vacuo and purified by silica gel column chromatography (petroleum ether-ethyl acetate, 4:1) to obtain 3.5 g of yellow liquid compound 3 in a yield of 36.5%. 1 H NMR(400MHz, DMSO-d6)δ7.78(d,J=8.8Hz,1H),7.41(t,J=8.9Hz,1H),4.25(s,2H), 3.54(s,2H),2.84(d,J=9.5Hz,3H),1.34(d,J=25.7Hz,9H).LC-MS:(ESI)m / z[M-55] + =365.0
[0149] 2) Preparation of Compound 4
[0150] Compound 3 (100 mg, 0.21 mmol) was added to 4 mL of 4 M hydrochloric acid in dioxane, and the suspension was stirred at room temperature for half an hour. The reaction mixture was then concentrated in vacuo to yield 75 mg of crude compound 4 as a yellow solid, in a 98.4% yield. LC-MS: (ESI) m / z [M+H] + =321.0
[0151] 3) Preparation of Compound 6
[0152] Compound 4 (300 mg, 0.94 mmol) was dissolved in 5 ml of methanol, and compound 5 (149 mg, 0.94 mmol), sodium triacetoxyborohydride (398 mg, 1.88 mmol) and acetic acid (5.83 mg, 0.094 mmol) were added. After stirring at room temperature for half an hour, the reaction mixture was poured into cold water and extracted with dichloromethane. The organic layer was washed with brine, dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel column chromatography (dichloromethane-methanol, 20:1) to obtain 340 mg of yellow liquid compound 6 with a yield of 78.5%. 1 H NMR (400MHz, DMSO-d6) δ7.77(dd,J=8.8,1.3Hz,1H),7.38(t,J=8.9Hz,1H),4.17(t,J=5.6Hz,2H),2.70(t,J=5.6Hz,2H),2. 36(t,J=7.0Hz,2H),2.21(s,3H),2.17(t,J=7.3Hz,2H),1.59(p,J=7.2Hz,2H),1.37(s,9H).LC-MS: (ESI)m / z[M+H]+=463.2
[0153] 4) Preparation of Compound 7
[0154] Compound 6 (340 mg, 0.74 mmol) and hydrazine hydrate (556 mg, 11.1 mmol) were added to 8 ml of n-butanol, and the suspension was heated at 110°C for 2 hours. The reaction mixture was then concentrated in vacuo and purified by silica gel column chromatography (petroleum ether-ethyl acetate, 1:1) to afford 280 mg of compound 7 as a yellow solid in an 80.3% yield. LC-MS: (ESI) m / z [M+H] + = 475.1
[0155] 5) Preparation of Compound 9
[0156] Compound 7 (500 mg, 1.05 mmol) was dissolved in a mixture of 12 ml of dimethyl ether and 4 ml of water, followed by the addition of compound 8 (276 mg, 1.26 mmol), tetrakis(triphenylphosphine)palladium (121 mg, 1.05 mmol), and sodium carbonate (223 mg, 2.1 mmol). The reaction mixture was heated to 80°C and allowed to react overnight under nitrogen. The reaction mixture was then concentrated in vacuo and purified by silica gel column chromatography (dichloromethane-methanol, 20:1) to afford 300 mg of compound 9 as a yellow solid in a 64.8% yield. 1 H NMR (400MHz, DMSO-d6) δ11.65(br,1H),7.07(d,J=8.3Hz,2H),6.74(d,J=7.7Hz,1H),6.65(d,J=8.3Hz,2H),6.58(d,J=7.7Hz,1H),5.18(s,2H),4.31 (s,2H),4.19(t,J=5.7Hz,2H),2.80(s,2H),2.43(s,2H),2.28(s,3H),2.2 2(t,J=7.2Hz,2H),1.70–1.60(m,2H),1.38(s,9H).LC-MS:(ESI)m / z[M+Na] + =462.2
[0157] 6) Preparation of Compound 11
[0158] Compound 9 (1.8 g, 4.1 mmol) was dissolved in 10 ml of dimethylformamide at 0°C, and compound 10 (620 mg, 4.1 mmol) was added. The reaction mixture was allowed to stand at room temperature and stirred for 2 hours. The reaction mixture was then concentrated in vacuo and purified by silica gel column chromatography (dichloromethane-methanol, 15:1) to afford 1.2 g of compound 11 as a yellow solid in a yield of 49.6%. LC-MS: (ESI) m / z [M+H] + =591.3
[0159] 7) Preparation of compound ST-06
[0160] 4.2 g of hydroxylamine hydrochloride and 2.4 g of sodium hydroxide were added to 25 ml of methanol and stirred at 0 ° C for half an hour. The reaction mixture was filtered to obtain a filtrate. Compound 11 (1.2 g, 2.19 mmol) and sodium hydroxide (1.75 g, 4.38 mmol) were added to 10 ml of the above filtrate and heated to 60 ° C constant temperature and stirred for 2 hours. The reaction mixture was then adjusted to pH 7 with 1 mol of hydrochloric acid. The reaction mixture was filtered to obtain a solid and purified by reversed-phase high performance liquid chromatography (0.1% acetic acid-acetonitrile and water). 590 mg of white solid compound ST-06 was obtained with a yield of 49.1%. 1 H NMR(400MHz,DMSO-d6)δ10.48(br,1H),9.34(s,1H),8.63(s,1H),8.24(s,1H),8.00(dd,J=7.8,1 .4Hz,1H),7.58(d,J=8.4Hz,2H),7.37(d,J=8.4Hz,2H),7.11(dd,J=11.2,8.4Hz,1H),6.81(d,J= 7.7Hz,2H),6.70(d,J=7.6Hz,1H),4.36–4.24(m,2H),3.03(s,2H),2.64(t,J=7 .0Hz,2H),2.45(s,3H),2.28(s,3H),2.06(t,J=6.9Hz,2H),1.87–1.66(m,2H). 13 C NMR(101MHz,DMSO-d6)δ169.5,164.4,152.7,152.0,149.6,149.0,143.4,139.1,134.2,134.0,133.3,129.8,128.3,1 27.6,127.5,123.2,123.2,121.5,112.0,118.4,115.1,114.9,112.3,106.7,65.6,56.8,55.5,42.1,30.4,22.4,21.2. 19 F NMR(376MHz,DMSO)δ-134.69.LC-MS:(ESI)m / z[M+H] + =550.2
[0161] Example 5 Evaluation of the Inhibition of HDAC1, HDAC6, VEGFR2 and PDGFR-β Activities by Compound ST-01, Compound ST-04 Hydrochloride, Compound ST-05 and Compound ST-06
[0162] 5.1 Purpose and Background
[0163] The goal of this experiment is to test the inhibitory ability of small molecule compounds against kinase activity using a kinase-based drug screening system. The HTRF method works as follows: a kinase phosphorylates a substrate; an Eu-labeled antibody binds to the phosphorylated site on the substrate; and streptavidin-XL665 binds to the substrate biotin. When Eu and XL665 are brought into close proximity, Eu, acting as a donor, is excited by a light source (320 nm) and emits light (615 nm). This energy is then resonantly transferred to the nearby acceptor XL665, which then emits light (665 nm). The specific signal is proportional to the phosphorylated substrate. When an inhibitor is added, phosphorylation is suppressed, and the 665 nm emission is no longer detectable, leaving only the 615 nm emission. This is used to assess the inhibitory effect of the compound on kinase activity. The ADP-Glo method works as follows: a kinase undergoes an enzymatic reaction with its substrate, consuming ATP to produce ADP. The amount of the product is measured using the ADP-Glo reagent and luminescence, reflecting the kinase activity.
[0164] 5.2 Test methods
[0165] 5.2.1 Enzyme reaction reagent formula
[0166] 5.2.1.1 Enzyme reaction formula
[0167] Enzyme reaction formula
[0168] 5.2.1.2 Substrate formulation
[0169] HDAC substrate formulation
[0170] VEGFR2 and PDGFR-β Substrate Formula
[0171] 5.2.2 Reagents and consumables
[0172] 5.2.3 Instruments
[0173] 5.2.4 Test steps
[0174] HDAC detection steps:
[0175] 1) Dilute the test compound with DMSO to 10 concentrations starting from 10 μM. Take 6 μL of the compound and add it to 54 μL of DMSO to perform a 3-fold dilution.
[0176] 2) Use Echo to transfer 50 nL of the test compound to a 384-well reaction plate, with two replicates for each compound. Centrifuge at 1000 rpm for 1 minute. The final DMSO concentration is 1%.
[0177] 3) Add 2.5 μL HDAC to the 384 reaction plate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 10 minutes.
[0178] 4) Add 2.5 μL of substrate to a 384-well reaction plate, centrifuge at 1000 rpm for 1 minute, and incubate at 37°C for 30 minutes.
[0179] 5) Add 5 μL of the developer mixture to the 384-well reaction plate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 10 minutes.
[0180] 6) Read the FI signal using a microplate reader (em: 340; ex: 450 nm).
[0181] VEGFR2 and PDGFR-β detection steps:
[0182] 1) Dilute the test compound with DMSO to 10 concentrations starting from 10 μM. Take 6 μL of the compound and add it to 54 μL of DMSO to perform a 3-fold dilution.
[0183] 2) Use Echo to transfer 25 nL of the test compound to a 384-well reaction plate, with two replicates for each compound. Centrifuge at 1000 rpm for 1 minute. The final DMSO concentration is 1%.
[0184] 3) Add 2.5 μL of kinase solution to a 384-well plate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 10 minutes.
[0185] 4) Add 2.5 μL ATP & Submixture to the 384 reaction plate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 50 minutes.
[0186] 5) Add 5 μL of Sa-XL 665 / TK-antibody-Cryptate to the 384 reaction plate, centrifuge at 1000 rpm for 1 minute, and incubate at 25°C for 1 hour.
[0187] 6) HTRF signal was read using a BMG high-throughput drug screening multifunctional microplate reader (Ratio 665 / 620 nm).
[0188] 5.2.3 Data Processing Method
[0189] The reading value of the negative control (1% DMSO well) was set as 0% inhibition rate, and the reading value of the positive control (positive drug well) was set as 100% inhibition rate, and the inhibition rate of each test solution was calculated.
[0190] :10μM Reference
[0191] : 1% DMSO
[0192] The IC of the compound was obtained using the following nonlinear fitting formula: 50 (half inhibitory concentration): Y = Bottom + (Top-Bottom) / (1 + 10^((LogIC 50 -X)×HillSlope))
[0193] X: Log value of compound concentration
[0194] Y: Compound inhibition rate (%inhibition)
[0195] Z' factor calculation equation: Z'=1-3(SD min +SD max ) / (AVE max -AVE min )
[0196] in:
[0197] Min is the positive control Ratio value, and Max is the negative control DMSO Ratio value.
[0198] SD is the standard error, and AVE is the mean value of Ratio.
[0199] 5.2.4 Experimental Results
[0200] Positive control: Vorinostat, Vorinostat:
[0201] Positive control: Sunitinib, Sunitinib:
[0202] Example 6 In vitro efficacy testing of compound ST-04 hydrochloride in 20 cell lines
[0203] 1. Research Objectives
[0204] use The in vitro efficacy of one test compound and one positive control drug on 20 cell lines was measured using the CTG method.
[0205] 2. Experimental Design
[0206] Determine the IC of 1 test compound and 1 positive compound in 20 cell lines 50 The drug treatment time was 3 days, with 9 concentrations and 3 replicates for each concentration.
[0207] 3. Materials
[0208] Cell line: Note: All cells were cultured at 37°C and 5% CO2.
[0209] 4. Reagents and consumables
[0210] 96-well plate (Corning, Cat. No. 3610)
[0211] MEM (Invitrogen, Catalog No.: 11095080)
[0212] RPMI 1640 (Invitrogen, Cat. No.: C22400500BT)
[0213] FBS (ExCell Bio, Cat. No.: FND500)
[0214] CellTiter-Glo (CTG) (Promega, Cat. No. G7573)
[0215] NEAA (GIBCO, item number: 11140050)
[0216] Penicillin-Streptomycin (Pen-Strep) (Gibco, Cat. No. 15070063)
[0217] 5. Test samples
[0218] Drug to be tested:
[0219] 6. Instruments
[0220] Envision 2104 Multilabel Reader: PerkinElmer (Instrument No.: TAREA0011);
[0221] CO2 incubator: SANYO Electric Co., Ltd. (instrument number: 02100400059);
[0222] Biological safety cabinet, Sujing Antai, BFC-1300IIA2 (instrument number: TBBSC0140);
[0223] Inverted microscope: Chongqing Optoelectronics XDS-1B (instrument number: TAMIC0200);
[0224] Viable cell counter: Vi-Cell XR, Beckman Coulter (instrument number: TACEL0030);
[0225] Electronic balance: Mettlertoledo AL104 (instrument number: TBBAL0560);
[0226] 7. Methods
[0227] 7.1. 2D Inhibitory Effects of Test Compounds on Cells
[0228] Cell culture
[0229] 1) Resuscitate cells in culture medium and maintain growth until the logarithmic phase. Digest with trypsin and harvest cells by centrifugation at 1000 rpm for 5 minutes. After centrifugation, remove the supernatant and resuspend the cells in an appropriate amount of culture medium.
[0230] Day 1: Cell plating
[0231] 2) Taking the cell suspension and counting the cells using a cell counter;
[0232] 3) Plate cells according to the desired number of cells to be tested. Add 90 μL of cell suspension to each well of a 96-well plate and set up the T0 plate.
[0233] 4) Cell culture was performed at 37°C, 5% CO2, and 95% humidity;
[0234] Day 2: T0 board readings
[0235] 5) Add 10 μL of medium containing solvent to each well and perform CTG analysis;
[0236] 6) Thaw the CTG reagent and equilibrate the cell plate to room temperature for 30 minutes;
[0237] 7) Add 50 μL of CTG solution to each well;
[0238] 8) Shake on an orbital shaker for 2 minutes to lyse the cells;
[0239] 9) Place the cell plate at room temperature for 10 minutes to stabilize the luminescence signal;
[0240] 10) Use EnVision to read the luminescence value;
[0241] Day 2: Add the drug to be tested
[0242] 11) Dissolve the test compound in a solvent to form a stock solution and perform a serial dilution, then dilute it 20-fold with culture medium to obtain a 10-fold solution;
[0243] Prepare a 10-fold solution of the positive drug in culture medium;
[0244] 12) Add 10 μL of 10X drug solution to each well (three replicates per cell concentration). The highest concentration of the test compound is 20 μM, with 9 concentrations and 3-fold dilutions.
[0245] 13) Cell culture was performed at 37°C and 5% CO2;
[0246] Day 5: Test plate readings (72 hours after drug treatment)
[0247] 14) Thaw the CTG reagent and equilibrate the cell plate to room temperature for 30 minutes;
[0248] 15) Add 100 μL CTG solution to each well;
[0249] 16) Shake on an orbital shaker for 2 minutes to lyse the cells;
[0250] 17) Place the cell plate at room temperature for 10 minutes to stabilize the luminescence signal.
[0251] 18) Use EnVision to read the luminescence value;
[0252] 8. Data Analysis
[0253] The cell survival rate is expressed as follows: (V sample -V Medium control ) / (V vehicle control -V Medium control )×100%. Where V sample is the reading of the drug-treated group, V vehicle control The S-shaped dose-survival curve was drawn using GraphPad Prism 9 software using a nonlinear regression model and the IC 50 The data also include the maximum inhibition rate.
[0254] 9. Experimental Results
[0255] 9.1. IC of the test compound on cells 50 and maximum inhibition rate suppression
[0256] The above experiments prove that the structure of the compound is accurate. Compared with the control sample, the compound of the present invention can simultaneously inhibit histone deacetylase VI (HDAC6, histone deacetylases 6), histone deacetylase 1 (HDAC1) and two tyrosine kinases (vascular endothelial growth factor receptor, Vascular endothelial cell growth factor2, VEGFR2) and platelet-derived growth factor receptor (platelet-derived growth factor-β, PDGFR-β). This shows that the compound of the present invention integrates multiple targets in one and can be used as a multi-target inhibitor, while having the pharmacological effects of sunitinib and vorinostat. Therefore, the compound of the present invention can be used to treat diseases mediated by tyrosine kinases and histone deacetylases, such as malignant tumors. Treatable malignant tumors include but are not limited to solid tumors such as renal cancer, liver cancer, colon cancer, gastrointestinal stromal tumors, lung cancer, breast cancer, pancreatic cancer, glioma, lymphoma, fibrosarcoma, ovarian cancer, prostate cancer, and malignant tumors of the blood system such as leukemia and lymphoma.
[0257] This type of compound combines multiple targets in one, which can not only give full play to the synergistic effect to increase biological activity, but also avoid the problems caused by the different properties and metabolism when multiple drugs are used in combination. It has good practicality and good prospects.
[0258] Furthermore, ST-04 hydrochloride demonstrated strong activity against all 20 tumor cell lines in in vitro efficacy testing, exceeding the positive control drug in most cases and being comparable to the positive control drug in the remainder. This demonstrates promising potential for the treatment of malignant tumors.
[0259] The above embodiments are intended only to illustrate the technical concepts and features of the present invention. Their purpose is to enable those skilled in the art to understand the contents of the present invention and implement them accordingly. They are not intended to limit the scope of protection of the present invention. Any equivalent changes or modifications made in accordance with the spirit of the present invention are intended to be covered by the scope of protection of the present invention.
[0260] The endpoints of the ranges and any values disclosed herein are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoints of each range, the endpoints of each range and individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered to be specifically disclosed herein.
Claims
1. A compound represented by the general formula (I), a pharmaceutically acceptable salt, hydrate or prodrug thereof, in: R a , R b are independently selected from hydrogen, C 1-20 alkyl, 3-10 membered heterocycloalkyl, 5-12 membered aromatic, 5-12 membered heteroaryl; wherein the C 1-20 The alkyl, 3-10 membered heterocycloalkyl, 5-12 membered aromatic, and 5-12 membered heteroaryl groups are each independently unsubstituted or substituted by one, two, three or more substituents selected from the group consisting of fluorine, chlorine, bromine, iodine, nitro, cyano, mercapto, hydroxyl, amino, C 1-6 Alkyl-substituted amino, C 1-10 Alkyl, halogenated C 1-6 Alkyl, nitro substituted C 1-6 Alkyl, cyano substituted C 1-6 Alkyl, thiol substituted C 1-6 Alkyl, amino substituted C 1-6 Alkyl, hydroxy substituted C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, nitro substituted C 1-6 Alkoxy, cyano substituted C 1-6 Alkoxy, mercapto substituted C 1-6 Alkoxy, amino substituted C 1-6 Alkoxy, hydroxy substituted C 1-6 Alkoxy, C 2-6 Alkenyl, C 2-6 Alkynyl, -C(=O)R1, -C(=O)NHR2, -C(=O)OR3, -NHC(=O)R4, -OC(=O)R5; R1, R2, R3, R4, R5 are independently selected from unsubstituted C 1-20 alkyl, or C substituted by one or more substituents independently selected from fluorine, chlorine, bromine, iodine, nitro, cyano, mercapto, hydroxyl, amino 1-20 alkyl; Each R c are the same or different and are each independently selected from hydrogen, C 1-20 Alkyl, C 1-20 Alkoxy, fluorine, chlorine, bromine, iodine, nitro, cyano, mercapto, hydroxyl, amino, C 1-6 Alkyl-substituted amino, halogenated C 1-6 Alkyl, nitro substituted C 1-6 Alkyl, cyano substituted C 1-6 Alkyl, thiol substituted C 1-6 Alkyl, amino substituted C 1-6 alkyl; R d , R e are independently selected from hydrogen, C 1-20 Alkyl, nitro substituted C 1-6 Alkyl, cyano substituted C 1-6 Alkyl, thiol substituted C 1-6 Alkyl, amino substituted C 1-6 alkyl; R g It has a chain structure, wherein the number of atoms constituting the main chain of the chain structure is 3-15 and the number of heteroatoms is not more than 2, and the heteroatoms are selected from oxygen, sulfur, and nitrogen; x is 1, 2, 3, or 4.
2. The compound according to claim 1, its pharmaceutically acceptable salt, hydrate or prodrug, characterized in that: The number of heteroatoms in the atoms constituting the main chain of the chain structure is 1 or 2, and one of the heteroatoms is connected to the benzene ring in the indazole ring.
3. The compound according to claim 1, its pharmaceutically acceptable salt, hydrate or prodrug, characterized in that: The chain structure is a saturated straight chain or a saturated branched chain.
4. The compound according to claim 1, its pharmaceutically acceptable salt, hydrate or prodrug, characterized in that: The compound has a structure shown by general formula (II): in: R a , R b , R c , R d , R e , x respectively correspond to R in the general formula (I) a , R b , R c , R d , R e , x are the same; A and B are independently CH2, O, S or -N(R6)-, R6 is hydrogen or C 1-6 Alkyl, m and n are independently selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 3≤m+n≤10; When any of the following conditions exists, B is CH2: (1) A is CH2; (2) A is selected from O, S or -N(R6)-, and m is 0; (3) n is 0.
5. The compound according to claim 4, its pharmaceutically acceptable salt, hydrate or prodrug, characterized in that: A is selected from CH2, O, S or -NH-, and B is selected from CH2, O, -N(CH3)-, -N(CH2CH3)- or -N(CH2CH2CH3)-.
6. The compound according to claim 4, its pharmaceutically acceptable salt, hydrate or prodrug, characterized in that: A is O, B is CH2, and m+n is 3, 4 or 5.
7. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt, hydrate or prodrug thereof, characterized in that: R a , R b Not at the same time as hydrogen.
8. The compound according to claim 7, its pharmaceutically acceptable salt, hydrate or prodrug, characterized in that: R a , R b wherein one is selected from pyrimidinyl, pyrazolyl, pyridinyl, pyrazinyl, imidazolyl, pyridazinyl, thiazolyl, phenyl, which are unsubstituted or substituted; and the other is selected from hydrogen, or C 1-6 alkyl.
9. The compound according to any one of claims 4 to 6, or a pharmaceutically acceptable salt, hydrate or prodrug thereof, characterized in that: The compound has a structure shown by general formula (III): in: R c , R d , R e , x, A, B, m, n are respectively the same as R in the general formula (ⅠI) c , R d , R e , x, A, B, m, n are the same; R b is selected from hydrogen, or from C which is unsubstituted or substituted by 1 to 3 halogens 1-6 alkyl; R7 is selected from fluorine, chlorine, bromine, iodine, hydroxyl, mercapto, cyano, amino, methylamino, ethylamino, nitro, C 1-6 Alkyl, halogenated C 1-6 Alkyl, C 1-6 Alkoxy, halogenated C 1-6 Alkoxy, hydroxymethyl, mercaptomethyl, C(=O)CH3, C(=O)CH2CH3, C(=O)NHCH3, C(=O)NHCH2CH3, NHC(=O)CH3, NHC(=O)CH2CH3, NHCH3, N(CH3)2, NHCH2CH3, t is 0, 1, 2, 3, 4 or 5, D and E are independently selected from CH or N.
10. The compound according to claim 9, or a pharmaceutically acceptable salt, hydrate or prodrug thereof, characterized in that: When t is 4, at least one of D and E is CH, and when t is 5, both D and E are CH.
11. The compound according to claim 9, or a pharmaceutically acceptable salt, hydrate or prodrug thereof, characterized in that: The compound has a structure shown in the general formula (IV): Where: R b , R c , R d , R e , x, A, B, m, n are respectively the same as R in the general formula (III) b , R c , R d , R e , x, A, B, m, n are the same; R8 and R9 are independently selected from hydrogen, fluorine, chlorine, bromine, iodine, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, halogenated methyl, halogenated ethyl, halogenated n-propyl, halogenated isopropyl, halogenated n-butyl, halogenated isobutyl, methoxy, ethoxy, halogenated methoxy, and halogenated ethoxy.
12. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt, hydrate or prodrug thereof, characterized in that: R b , R d , R e are independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl or isobutyl.
13. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt, hydrate or prodrug thereof, characterized in that: Each R c are the same or different and are each independently selected from hydrogen, fluorine, chlorine, bromine, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, methoxy or ethoxy.
14. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt, hydrate or prodrug thereof, characterized in that: R b , R c , R d , R e At the same time, it is hydrogen.
15. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt, hydrate or prodrug thereof, characterized in that: R g Selected from:
16. The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or prodrug thereof, characterized in that: The compound has a structure shown in general formula (V): Wherein: p is 2, 3, 4, 5, 6, 7, 8, 9 or 10; R8, R9 are independently selected from hydrogen, fluorine, chlorine, bromine, iodine, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, halogenated methyl, halogenated ethyl, halogenated n-propyl, halogenated isopropyl, halogenated n-butyl, halogenated isobutyl, methoxy, ethoxy, halogenated methoxy, halogenated ethoxy.
17. The compound according to claim 1, or a pharmaceutically acceptable salt, hydrate or prodrug thereof, characterized in that: The structural formula of the compound is shown in any one of formulas (ST-01) to (ST-16):
18. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the compound according to any one of claims 1 to 17, a pharmaceutically acceptable salt, hydrate or prodrug thereof, and a pharmaceutically acceptable carrier.
19. The pharmaceutical composition according to claim 18, characterized in that The pharmaceutical composition is a composition for preventing and / or treating malignant tumors, including renal cancer, liver cancer, colon cancer, gastrointestinal stromal tumors, lung cancer, breast cancer, pancreatic cancer, glioma, lymphoma, fibrosarcoma, ovarian cancer, prostate cancer, leukemia, and lymphoma.
20. Use of the compound according to any one of claims 1 to 17, its pharmaceutically acceptable salt, hydrate or prodrug, or the pharmaceutical composition according to claim 18 in the preparation of a medicament for preventing and / or treating diseases mediated by tyrosine kinase and / or histone deacetylase.
21. The use according to claim 20, characterized in that The tyrosine kinases include vascular endothelial growth factor receptor and platelet-derived growth factor receptor, and the histone deacetylases include histone deacetylase 1 and histone deacetylase 6.
Citation Information
Patent Citations
Novel hydroxamic acid derivative and medical application thereof
CN103396417A
Novel naphthoyl urea derivate and medical application thereof
CN103524421A
Hydroximic acid derivative containing indazolyl and application thereof
CN116535359A
Methods for treating small cell neuroendocrine and related cancers
WO2020243329A1
